This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zennou, V.
Right arrow Articles by Bieniasz, P. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zennou, V.
Right arrow Articles by Bieniasz, P. D.

 Previous Article  |  Next Article 

Journal of Virology, November 2004, p. 12058-12061, Vol. 78, No. 21
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.21.12058-12061.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

APOBEC3G Incorporation into Human Immunodeficiency Virus Type 1 Particles

Véronique Zennou,1 David Perez-Caballero,1 Heinrich Göttlinger,2 and Paul D. Bieniasz1*

Aaron Diamond AIDS Research Center and the Rockefeller University, New York, New York,1 Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, and Department of Pathology, Harvard Medical School, Boston, Massachusetts2

Received 2 April 2004/ Accepted 5 July 2004


arrow
ABSTRACT
 
APOBEC3G is promiscuous with respect to its antiretroviral effect, requiring that it be packaged into diverse retrovirus particles. Here, we show that most virally encoded human immunodeficiency virus type 1 particle components are dispensable for APOPEC3G incorporation. However, replacement of the nucleocapsid (NC) Gag domain with a leucine zipper abolished APOBEC3G incorporation. Moreover, coprecipitation analysis showed that APOBEC3G-Gag interaction requires NC and nonspecific RNA. These observations suggest that APOBEC3G exploits an essential property of retroviruses, namely, RNA packaging, to infiltrate particles. Because it is, therefore, difficult to evolve specific sequences that confer escape from APOBEC3G, these findings may explain why lentiviruses evolved an activity that induces its destruction.


arrow
TEXT
 
APOBEC3G is a cytidine deaminase that modifies nascent single-stranded retroviral DNA during reverse transcription (19), resulting in its degradation or hypermutation (6, 10, 12, 24). Although APOBEC3G acts during the early phases of the retrovirus life cycle, antiviral activity is observed only if APOBEC3G is expressed in the cell from which the virion is derived (6, 12, 13, 24). These findings suggest that a sequestered environment for reverse transcription that incorporates APOBEC3G is defined in virus-producing cells and is at least temporarily preserved upon subsequent infection of target cells. Accordingly, APOBEC3G incorporation into retroviral particles has been demonstrated (6, 13, 19). Most lentiviruses counteract this antiretroviral activity by expressing Vif proteins that prevent APOBEC3G incorporation into virions, primarily by inducing its degradation by proteasomes (4, 9, 11, 14, 17, 20, 21, 23) and perhaps by additional mechanisms (13, 21).

A feature of the antiretroviral activity exhibited by APOBEC3G is its broad specificity. Human immunodeficiency virus type 1 (HIV-1), a variety of simian immunodeficiency viruses, and more distantly related retroviruses, such as equine infectious anemia virus and murine leukemia virus, are inhibited by human APOBEC3G (6, 12, 13). Therefore, APOBEC3G must have the remarkable ability to be packaged into diverse retroviral particles whose protein and nucleic acid components exhibit little sequence homology. Here, we set out to determine what viral components mediate the packaging of APOBEC3G into HIV-1 particles that might explain this promiscuity.

Viral genomic RNA and virion proteins other than Gag are not required for APOBEC3G packaging. APOBEC3G is active in experimental contexts that employ retroviral vector systems to deliver heterologous genes (6, 12). Typically, vector systems package versions of the cognate viral genome, where the majority of viral RNA sequences have been removed. Nonetheless, vector RNAs must retain certain cis-acting signals, such as those required for packaging (2), that could, in principle, be structurally conserved and responsible for recruitment and packaging of APOBEC3G into retroviral particles. Therefore, we first tested whether particles generated by expression of HIV-1 Gag-Pol proteins alone or in the presence of a packageable vector RNA genome differed in their ability to incorporate APOBEC3G. In this and other experiments, 293T cells in 35-mm-diameter dishes were transfected with plasmids expressing HIV-1 Gag-Pol proteins (7) and an amino-terminally myc-tagged APOBEC3G protein in the presence or absence of an HIV-1 vector genome expression plasmid, CSGW (5). As a control for nonspecific protein packaging and cellular debris contamination of particle preparations, an irrelevant myc-tagged cytoplasmic protein (green fluorescent protein [GFP]) was expressed in place of myc-APOBEC3G. Forty-eight hours after transfection, culture supernatants were clarified by low-speed centrifugation and passed through a 0.22-µm-pore-size filter. Particles were recovered by ultracentrifugation through a 20% sucrose cushion. Thereafter, cell and viral particle lysates were analyzed by Western blotting with anti-CA and anti-myc monoclonal antibodies, as previously described (16). As can be seen in Fig. 1A, the levels of APOBEC3G in cell and virion lysates were unaffected by the presence or absence of a packageable genome. Thus, Gag-Pol proteins are sufficient to mediate APOBEC3G incorporation into HIV-1 particles.



View larger version (31K):
[in this window]
[in a new window]
  		FIG. 1. Effect of HIV-1 virion protein and RNA composition on APOBEC3G incorporation into viral particles. (A) Western blot (WB) analyses of cell lysates (left panels) and extracellular VLPs (right panels) generated following transfection of 293T cells with plasmids expressing HIV-1 Gag-Pol and either myc-tagged APOBEC3G or myc-tagged GFP. A plasmid expressing a packageable RNA genome was included where indicated. The upper panels show Western blots probed with an anti-HIV-1 CA antibody, and the positions of the Gag precursor (Pr55 Gag) and processed p24 capsid (p24 CA) are indicated. The blots in the lower panels were probed with an anti-myc epitope antibody. Note that the VLP blots probed with the anti-myc antibody were exposed approximately 10-fold longer than the cell lysate blots. (B) Schematic representation of plasmids used to express HXB Gag from viral RNA-derived sequences (pCR/V1/HXB Gag; upper diagram) or a synthetic codon-optimized RNA (pCR3.1/synGag; lower diagram). (C) Western blot analyses of cell lysates (left panels) and extracellular VLPs (right panels) generated following transfection of 293T cells with plasmids expressing synGag or HXB Gag and myc-tagged APOBEC3G. {alpha}, anti; BGH, bovine growth hormone; CMV, cytomegalovirus.

We next tested whether Gag alone was sufficient to generate virus-like particles (VLPs) that incorporated APOBEC3G. An HXB-derived HIV-1 Gag protein, expressed by using a hybrid expression plasmid, pCR/V1 (shown schematically in Fig. 1B), generated VLPs that incorporated APOBEC3G as efficiently as Gag-Pol VLPs (Fig. 1C). However, because the plasmid (pCR/V1) used to generate Gag and Gag-Pol VLPs in Fig. 1A and C and in Fig. 2 included elements of the HIV-1 genomic RNA, including the 5' untranslated nucleotides 1 through 330, it is possible that low levels of deleted viral RNA were incorporated into VLPs and that this RNA was responsible for APOBEC3G incorporation. Therefore, we also generated Gag VLPs, using an entirely synthetic, codon-optimized Gag(synGag) expression plasmid. This pCR3.1 (Invitrogen)-based construct expresses a Gag protein with the same amino acid sequence as that of HXB Gag but completely lacks flanking viral RNA sequences. Moreover, the RNA encoding the Gag protein is quite different from the viral RNA that normally encodes HXB Gag. Thus, it is impossible for these VLPs to contain any viral RNA, because none is present in the expression system. As shown in Fig. 1C, these VLPs incorporated APOBEC3G at least as efficiently as those generated using pCR/V1-based Gag or Gag-Pol expression vectors. We conclude that Gag protein is the only virally encoded component of virions that is essential for APOBEC3G incorporation.




View larger version (62K):
[in this window]
[in a new window]
  		FIG. 2. NC, but not the majority of Gag, is required for APOBEC3G incorporation into HIV-1 VLPs. (A) Schematic representation of the intact HIV-1 Gag precursor and the deletion mutants used in this study. The positions of the major homology region (MHR) and the various Gag cleavage sites are shown. (B) Western blot (WB) analyses of cell lysates (left panels) and extracellular VLPs (right panels) generated following transfection of 293T cells with plasmids expressing HIV-1 Gag or the deletion mutants shown in panel A and myc-tagged APOBEC3G. Blots were probed with anti-HIV-1 CA or anti-myc antibodies, as described in the legend to Fig. 1. (C) Schematic representation of the intact HIV-1 Gag precursor and its derivative, Zwt-p6. (D) Western blot analyses of cell lysates (left panels) and extracellular VLPs (right panels) generated following transfection of 293T cells with plasmids expressing HIV-1 Gag or Zwt-p6 and either myc-tagged APOBEC3G or myc-tagged GFP. The upper panels show Western blots probed with an anti-HIV-1 CA antibody, and the positions of the Gag and Zwt-p6 proteins are indicated. The blots in the lower panels were probed with an anti-myc epitope antibody. (E) Quantitation of RNA in wild-type Gag and Zwt-p6 VLPs, as determined by Ribogreen analysis of one-fifth of the VLPs pelleted from 30 ml of 293T cell supernatants. Pelletable material released from control-vector-transfected 293T cells was also analyzed as a control. A fourfold dilution series of the same wild-type Gag and Zwt-p6 VLPs was analyzed by Western blotting (right) to verify that equivalent amounts of VLPs were included in the Ribogreen analyses. {alpha}, anti.

The majority of Gag is dispensable for APOBEC3G packaging. We next used deletion mutants to determine whether parts of Gag were dispensable for APOBEC3G packaging into virions. Two Gag deletion mutants, lacking residues 10 through 110 (the {delta}10-110 mutant) or residues 10 through 277 (the {delta}10-277 mutant) (Fig. 2A), were tested. In both cases, myc-APOBEC3G, but not myc-GFP, was efficiently incorporated into VLPs (Fig. 2B and data not shown). Thus, almost all matrix and the amino-terminal two-thirds of capsid are dispensable for APOBEC3G packaging.

The HIV-1 Gag NC domain is required for APOBEC3G packaging. The aforementioned {delta}10-277 HIV-1 Gag protein has undergone what is nearly the largest deletion that can be tolerated by HIV-1 Gag while retaining the ability to form extracellular particles (1, 3). However, the interaction, or I, domain, encoded within NC, as well as the late budding, or L, domain, encoded within p6 Gag, can be replaced by heterologous sequences, yielding chimeric Gag proteins that retain particle-forming activity (1, 15, 22). Therefore, we tested whether an HIV-1 Gag protein termed Zwt-p6 (1), in which NC is replaced by a leucine zipper from GCN4 (Fig. 2C), could package APOBEC3G. An otherwise identical HXB-derived Gag protein was used as a control. Particles formed by the wild-type HXB Gag protein incorporated myc-APOBEC3G but not myc-GFP (Fig. 2D), but those formed by Zwt-p6 did not incorporate either protein. Thus, the NC Gag domain is required for incorporation of APOBEC3G into HIV-1 VLPs.

Some conserved features of retroviral NC proteins are the zinc fingers and basic residues that are required for the incorporation of RNA (2). Although we had excluded the possibility that specific HIV-1 RNA sequences mediated APOBEC3G incorporation (Fig. 1), retroviral Gag proteins can package nonspecific RNA into particles in the absence of viral genomes (2). Indeed, RNA-induced multimerization of Gag monomers may be required for particle assembly when Gag contains an authentic NC domain (18). Potentially, nonspecific RNA might be responsible for recruiting APOBEC3G into HIV-1 VLPs. We therefore measured the levels of RNA associated with VLPs generated by the HXB Gag and Zwt-p6 proteins, using a strategy similar to that described previously (18). VLPs were harvested from 30 ml of DNase I-treated 293T cell supernatant by ultracentrifugation through 20% sucrose, resuspended in 100 µl of phosphate-buffered saline-1% Triton X-100, and heated at 56°C. The RNA content in the pelleted material was measured with Ribogreen molecular probes. As can be seen in Fig. 2E, wild-type Gag VLPs contained four- to eightfold-higher levels of RNA than did Zwt-p6 VLPs. In fact, the levels of RNA in Zwt-p6 VLP pellets were only slightly higher than the background levels of pelletable RNA in the supernatant of cells transfected with a control plasmid vector (Fig. 2E). Thus, this result indicated that NC protein, nonspecific RNA, or both could be responsible for recruiting APOBEC3G into VLPs.

APOBEC3G physically associates with NC in an RNA-dependent manner. We next determined whether APOBEC3G physically associated with Gag or fragments of Gag in mammalian cells, by use of a previously described glutathione S-transferase (GST) fusion protein coprecipitation assay (15). myc-tagged APOBEC3G and GFP proteins were coexpressed in 293T cells with GST-fused HIV-1 synGag (or fragments thereof) (Fig. 3A). Thereafter, cell lysates were incubated with glutathione-Sepharose beads that were subsequently washed, and bound proteins were analyzed by Western blotting with anti-myc antibodies. As can be seen in Fig. 3B, intact HIV-1 Gag-GST or fragments (p2NCp1p6-GST and NC-GST) containing the NC Gag domain bound to APOBEC3G, while other Gag-GST fragments did not. Taken together, the results in Fig. 2 and 3B indicate that some form of interaction between NC and APOBEC3G is responsible for APOBEC3G incorporation into HIV-1 particles.




View larger version (89K):
[in this window]
[in a new window]
  		FIG. 3. NC binds to APOBEC3G in an RNA-dependent manner. (A) Schematic representation of intact and fragmented Gag-GST fusion proteins. MHR, major homology region. (B) Gag-GST fusion proteins were coexpressed with myc-APOBEC3G (left panels) or myc-GFP (right panels). The upper and middle panels show Western blot (WB) analyses of total cell lysates. The blots in the upper panels were probed with an anti-GST antibody, and the blots in the middle panels were probed with an anti-myc antibody. The lower panels show a Western analysis (blots probed with an anti-myc antibody) of proteins precipitated from each of the cell lysates by glutathione-Sepharose beads. (C) The same experiment illustrated in the left panels of panel B was done, and Western blot analyses of the glutathione-bound proteins are shown. myc-APOBEC3G was precipitated by Gag-GST fusion proteins from duplicate aliquots of cell lysates that were left untreated (upper panel) or treated with RNase A (lower panel).

We therefore tested whether the interaction that we observed between HIV-1 Gag and APOBEC3G was dependent on the presence of RNA by repeating the coprecipitation experiment illustrated in Fig. 3B, but in the presence or absence of RNase A. As can be seen in Fig. 3C, the ability of the Gag-GST fusion proteins to coprecipitate APOBEC3G was inhibited when 50 µg of RNase A per ml was added to the cell lysate. Thus, RNA is required for the interaction between HIV-1 Gag and APOBEC3G.

Conclusions. Based on the ability of APOBEC3G to be incorporated into HIV-1 VLPs in an NC-dependent manner and to physically associate with HIV-1 NC and Gag only in the presence of RNA, we conclude that NC recruits APOBEC3G into HIV-1 virions via interactions with RNA. While we cannot discount the possibility that specific protein-protein contacts exist between APOBEC3G and Gag, if these do occur, they appear insufficient for stable interaction. At a minimum, RNA strongly facilitates APOBEC3G-Gag interaction, and it may be that RNA is only virion molecule bound by APOBEC3G. In fact, APOBEC3G has previously been shown to bind AU-rich RNA (8). These observations suggest that APOBEC3G exploits the obligate RNA-packaging activity of Gag proteins to infiltrate virus particles. Because it would therefore be unlikely for retroviruses to evolve specific APOBEC3G "escape mutants," these findings may explain why lentiviruses have taken the extraordinary evolutionary step of acquiring an additional gene whose sole function is to remove APOBEC3G from the cell (6, 12, 13).


arrow
ACKNOWLEDGMENTS
 
We thank Cameron Bess for assistance and Theodora Hatziioannou and Juan Martin-Serrano for helpful advice.

This work was supported by NIH grants R01AI50111 (to P.D.B.) and R01 50466 (to H.G.). P.D.B. is an Elizabeth Glaser Scientist of the Elizabeth Glaser Pediatric AIDS Foundation.


arrow
FOOTNOTES
 
* Corresponding Author. Mailing Address: Aaron Diamond AIDS Research Center, 455 First Ave., New York, NY 10016. Phone: (212) 448-5070. Fax: (212) 725-1126. E-mail: pbienias{at}adarc.org. Back


arrow
REFERENCES
 
    1
  1. Accola, M. A., B. Strack, and H. G. Gottlinger. 2000. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J. Virol. 74:5395-5402.[Abstract/Free Full Text]
    2. 2
  2. Berkowitz, R., J. Fisher, and S. P. Goff. 1996. RNA packaging. Curr. Top. Microbiol. Immunol. 214:177-218.[Medline]
    3. 3
  3. Borsetti, A., A. Ohagen, and H. G. Gottlinger. 1998. The C-terminal half of the human immunodeficiency virus type 1 Gag precursor is sufficient for efficient particle assembly. J. Virol. 72:9313-9317.[Abstract/Free Full Text]
    4. 4
  4. Conticello, S. G., R. S. Harris, and M. S. Neuberger. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13:2009-2013.[CrossRef][Medline]
    5. 5
  5. Demaison, C., K. Parsley, G. Brouns, M. Scherr, K. Battmer, C. Kinnon, M. Grez, and A. J. Thrasher. 2002. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum. Gene Ther. 13:803-813.[CrossRef][Medline]
    6. 6
  6. Harris, R. S., K. N. Bishop, A. M. Sheehy, H. M. Craig, S. K. Petersen-Mahrt, I. N. Watt, M. S. Neuberger, and M. H. Malim. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809.[CrossRef][Medline]
    7. 7
  7. Hatziioannou, T., S. Cowan, and P. D. Bieniasz. 2004. Capsid-dependent and -independent postentry restriction of primate lentivirus tropism in rodent cells. J. Virol. 78:1006-1011.[Abstract/Free Full Text]
    8. 8
  8. Jarmuz, A., A. Chester, J. Bayliss, J. Gisbourne, I. Dunham, J. Scott, and N. Navaratnam. 2002. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79:285-296.[CrossRef][Medline]
    9. 9
  9. Kao, S., M. A. Khan, E. Miyagi, R. Plishka, A. Buckler-White, and K. Strebel. 2003. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77:11398-11407.[Abstract/Free Full Text]
    10. 10
  10. Lecossier, D., F. Bouchonnet, F. Clavel, and A. J. Hance. 2003. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112.[Free Full Text]
    11. 11
  11. Liu, B., X. Yu, K. Luo, Y. Yu, and X.-F. Yu. 2004. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J. Virol. 78:2072-2081.[Abstract/Free Full Text]
    12. 12
  12. Mangeat, B., P. Turelli, G. Caron, M. Friedli, L. Perrin, and D. Trono. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103.[CrossRef][Medline]
    13. 13
  13. Mariani, R., D. Chen, B. Schrofelbauer, F. Navarro, R. Konig, B. Bollman, C. Munk, H. Nymark-McMahon, and N. R. Landau. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31.[CrossRef][Medline]
    14. 14
  14. Marin, M., K. M. Rose, S. L. Kozak, and D. Kabat. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398-1403.[CrossRef][Medline]
    15. 15
  15. Martin-Serrano, J., A. Yarovoy, D. Perez-Caballero, and P. D. Bieniasz. 2003. Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. Proc. Natl. Acad. Sci. USA 100:12414-12419.[Abstract/Free Full Text]
    16. 16
  16. Martin-Serrano, J., T. Zang, and P. D. Bieniasz. 2001. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat. Med. 7:1313-1319.[CrossRef][Medline]
    17. 17
  17. Mehle, A., B. Strack, P. Ancuta, C. Zhang, M. McPike, and D. Gabuzda. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279:7792-7798.[Abstract/Free Full Text]
    18. 18
  18. Muriaux, D., J. Mirro, D. Harvin, and A. Rein. 2001. RNA is a structural element in retrovirus particles. Proc. Natl. Acad. Sci. USA 98:5246-5251.[Abstract/Free Full Text]
    19. 19
  19. Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.[CrossRef][Medline]
    20. 20
  20. Sheehy, A. M., N. C. Gaddis, and M. H. Malim. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407.[CrossRef][Medline]
    21. 21
  21. Stopak, K., C. de Noronha, W. Yonemoto, and W. C. Greene. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12:591-601.[CrossRef][Medline]
    22. 22
  22. Strack, B., A. Calistri, M. A. Accola, G. Palu, and H. G. Gottlinger. 2000. A role for ubiquitin ligase recruitment in retrovirus release. Proc. Natl. Acad. Sci. USA 97:13063-13068.[Abstract/Free Full Text]
    23. 23
  23. Yu, X., Y. Yu, B. Liu, K. Luo, W. Kong, P. Mao, and X. F. Yu. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060.[Abstract/Free Full Text]
    24. 24
  24. Zhang, H., B. Yang, R. J. Pomerantz, C. Zhang, S. C. Arunachalam, and L. Gao. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98.[CrossRef][Medline]

Journal of Virology, November 2004, p. 12058-12061, Vol. 78, No. 21
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.21.12058-12061.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Le Tortorec, A., Neil, S. J. D. (2009). Antagonism to and Intracellular Sequestration of Human Tetherin by the Human Immunodeficiency Virus Type 2 Envelope Glycoprotein. J. Virol. 83: 11966-11978 [Abstract] [Full Text]  
  • Jouvenet, N., Simon, S. M., Bieniasz, P. D. (2009). Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles. Proc. Natl. Acad. Sci. USA 106: 19114-19119 [Abstract] [Full Text]  
  • Chen, G., He, Z., Wang, T., Xu, R., Yu, X.-F. (2009). A Patch of Positively Charged Amino Acids Surrounding the Human Immunodeficiency Virus Type 1 Vif SLVx4Yx9Y Motif Influences Its Interaction with APOBEC3G. J. Virol. 83: 8674-8682 [Abstract] [Full Text]  
  • Guo, F., Saadatmand, J., Niu, M., Kleiman, L. (2009). Roles of Gag and NCp7 in Facilitating Formula Annealing to Viral RNA in Human Immunodeficiency Virus Type 1. J. Virol. 83: 8099-8107 [Abstract] [Full Text]  
  • Henriet, S., Mercenne, G., Bernacchi, S., Paillart, J.-C., Marquet, R. (2009). Tumultuous Relationship between the Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) and the Human APOBEC-3G and APOBEC-3F Restriction Factors. Microbiol. Mol. Biol. Rev. 73: 211-232 [Abstract] [Full Text]  
  • Malim, M. H (2009). APOBEC proteins and intrinsic resistance to HIV-1 infection. Phil Trans R Soc B 364: 675-687 [Abstract] [Full Text]  
  • Chiu, Y.-L., Greene, W. C (2009). APOBEC3G: an intracellular centurion. Phil Trans R Soc B 364: 689-703 [Abstract] [Full Text]  
  • Crist, R. M., Datta, S. A. K., Stephen, A. G., Soheilian, F., Mirro, J., Fisher, R. J., Nagashima, K., Rein, A. (2009). Assembly Properties of Human Immunodeficiency Virus Type 1 Gag-Leucine Zipper Chimeras: Implications for Retrovirus Assembly. J. Virol. 83: 2216-2225 [Abstract] [Full Text]  
  • Jouvenet, N., Neil, S. J. D., Zhadina, M., Zang, T., Kratovac, Z., Lee, Y., McNatt, M., Hatziioannou, T., Bieniasz, P. D. (2009). Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin. J. Virol. 83: 1837-1844 [Abstract] [Full Text]  
  • Khatua, A. K., Taylor, H. E., Hildreth, J. E. K., Popik, W. (2009). Exosomes Packaging APOBEC3G Confer Human Immunodeficiency Virus Resistance to Recipient Cells. J. Virol. 83: 512-521 [Abstract] [Full Text]  
  • Ikeda, T., Ohsugi, T., Kimura, T., Matsushita, S., Maeda, Y., Harada, S., Koito, A. (2008). The antiretroviral potency of APOBEC1 deaminase from small animal species. Nucleic Acids Res 36: 6859-6871 [Abstract] [Full Text]  
  • Bogerd, H. P., Tallmadge, R. L., Oaks, J. L., Carpenter, S., Cullen, B. R. (2008). Equine Infectious Anemia Virus Resists the Antiretroviral Activity of Equine APOBEC3 Proteins through a Packaging-Independent Mechanism. J. Virol. 82: 11889-11901 [Abstract] [Full Text]  
  • Bennett, R. P., Salter, J. D., Liu, X., Wedekind, J. E., Smith, H. C. (2008). APOBEC3G Subunits Self-associate via the C-terminal Deaminase Domain. J. Biol. Chem. 283: 33329-33336 [Abstract] [Full Text]  
  • Nguyen, D. H., Hu, J. (2008). Reverse Transcriptase- and RNA Packaging Signal-Dependent Incorporation of APOBEC3G into Hepatitis B Virus Nucleocapsids. J. Virol. 82: 6852-6861 [Abstract] [Full Text]  
  • Knoepfel, S. A., Salisch, N. C., Huelsmann, P. M., Rauch, P., Walter, H., Metzner, K. J. (2008). Comparison of G-to-A Mutation Frequencies Induced by APOBEC3 Proteins in H9 Cells and Peripheral Blood Mononuclear Cells in the Context of Impaired Processivities of Drug-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptase Variants. J. Virol. 82: 6536-6545 [Abstract] [Full Text]  
  • Bogerd, H. P., Cullen, B. R. (2008). Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA 14: 1228-1236 [Abstract] [Full Text]  
  • Langlois, M.-A., Neuberger, M. S. (2008). Human APOBEC3G Can Restrict Retroviral Infection in Avian Cells and Acts Independently of both UNG and SMUG1. J. Virol. 82: 4660-4664 [Abstract] [Full Text]  
  • Bennett, R. P., Presnyak, V., Wedekind, J. E., Smith, H. C. (2008). Nuclear Exclusion of the HIV-1 Host Defense Factor APOBEC3G Requires a Novel Cytoplasmic Retention Signal and Is Not Dependent on RNA Binding. J. Biol. Chem. 283: 7320-7327 [Abstract] [Full Text]  
  • Popov, S., Popova, E., Inoue, M., Gottlinger, H. G. (2008). Human Immunodeficiency Virus Type 1 Gag Engages the Bro1 Domain of ALIX/AIP1 through the Nucleocapsid. J. Virol. 82: 1389-1398 [Abstract] [Full Text]  
  • Browne, E. P., Littman, D. R. (2008). Species-Specific Restriction of Apobec3-Mediated Hypermutation. J. Virol. 82: 1305-1313 [Abstract] [Full Text]  
  • Tian, C., Wang, T., Zhang, W., Yu, X.-F. (2007). Virion packaging determinants and reverse transcription of SRP RNA in HIV-1 particles. Nucleic Acids Res 35: 7288-7302 [Abstract] [Full Text]  
  • Wiegand, H. L., Cullen, B. R. (2007). Inhibition of Alpharetrovirus Replication by a Range of Human APOBEC3 Proteins. J. Virol. 81: 13694-13699 [Abstract] [Full Text]  
  • Miyagi, E., Opi, S., Takeuchi, H., Khan, M., Goila-Gaur, R., Kao, S., Strebel, K. (2007). Enzymatically Active APOBEC3G Is Required for Efficient Inhibition of Human Immunodeficiency Virus Type 1. J. Virol. 81: 13346-13353 [Abstract] [Full Text]  
  • Virgen, C. A., Hatziioannou, T. (2007). Antiretroviral Activity and Vif Sensitivity of Rhesus Macaque APOBEC3 Proteins. J. Virol. 81: 13932-13937 [Abstract] [Full Text]  
  • Wang, T., Tian, C., Zhang, W., Luo, K., Sarkis, P. T. N., Yu, L., Liu, B., Yu, Y., Yu, X.-F. (2007). 7SL RNA Mediates Virion Packaging of the Antiviral Cytidine Deaminase APOBEC3G. J. Virol. 81: 13112-13124 [Abstract] [Full Text]  
  • Li, X.-Y., Guo, F., Zhang, L., Kleiman, L., Cen, S. (2007). APOBEC3G Inhibits DNA Strand Transfer during HIV-1 Reverse Transcription. J. Biol. Chem. 282: 32065-32074 [Abstract] [Full Text]  
  • Guo, F., Cen, S., Niu, M., Yang, Y., Gorelick, R. J., Kleiman, L. (2007). The Interaction of APOBEC3G with Human Immunodeficiency Virus Type 1 Nucleocapsid Inhibits tRNA3Lys Annealing to Viral RNA. J. Virol. 81: 11322-11331 [Abstract] [Full Text]  
  • Bernacchi, S., Henriet, S., Dumas, P., Paillart, J.-C., Marquet, R. (2007). RNA and DNA Binding Properties of HIV-1 Vif Protein: A FLUORESCENCE STUDY. J. Biol. Chem. 282: 26361-26368 [Abstract] [Full Text]  
  • Henriet, S., Sinck, L., Bec, G., Gorelick, R. J., Marquet, R., Paillart, J.-C. (2007). Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Res 35: 5141-5153 [Abstract] [Full Text]  
  • Luo, K., Wang, T., Liu, B., Tian, C., Xiao, Z., Kappes, J., Yu, X.-F. (2007). Cytidine Deaminases APOBEC3G and APOBEC3F Interact with Human Immunodeficiency Virus Type 1 Integrase and Inhibit Proviral DNA Formation. J. Virol. 81: 7238-7248 [Abstract] [Full Text]  
  • Burnett, A., Spearman, P. (2007). APOBEC3G Multimers Are Recruited to the Plasma Membrane for Packaging into Human Immunodeficiency Virus Type 1 Virus-Like Particles in an RNA-Dependent Process Requiring the NC Basic Linker. J. Virol. 81: 5000-5013 [Abstract] [Full Text]  
  • Huthoff, H., Malim, M. H. (2007). Identification of Amino Acid Residues in APOBEC3G Required for Regulation by Human Immunodeficiency Virus Type 1 Vif and Virion Encapsidation. J. Virol. 81: 3807-3815 [Abstract] [Full Text]  
  • Gallois-Montbrun, S., Kramer, B., Swanson, C. M., Byers, H., Lynham, S., Ward, M., Malim, M. H. (2007). Antiviral Protein APOBEC3G Localizes to Ribonucleoprotein Complexes Found in P Bodies and Stress Granules. J. Virol. 81: 2165-2178 [Abstract] [Full Text]  
  • Derse, D., Hill, S. A., Princler, G., Lloyd, P., Heidecker, G. (2007). Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc. Natl. Acad. Sci. USA 104: 2915-2920 [Abstract] [Full Text]  
  • Wang, X., Dolan, P. T., Dang, Y., Zheng, Y.-H. (2007). Biochemical Differentiation of APOBEC3F and APOBEC3G Proteins Associated with HIV-1 Life Cycle. J. Biol. Chem. 282: 1585-1594 [Abstract] [Full Text]  
  • Doehle, B. P., Bogerd, H. P., Wiegand, H. L., Jouvenet, N., Bieniasz, P. D., Hunter, E., Cullen, B. R. (2006). The Betaretrovirus Mason-Pfizer Monkey Virus Selectively Excludes Simian APOBEC3G from Virion Particles. J. Virol. 80: 12102-12108 [Abstract] [Full Text]  
  • Guo, F., Cen, S., Niu, M., Saadatmand, J., Kleiman, L. (2006). Inhibition of Formula-Primed Reverse Transcription by Human APOBEC3G during Human Immunodeficiency Virus Type 1 Replication. J. Virol. 80: 11710-11722 [Abstract] [Full Text]  
  • Jonsson, S. R., Hache, G., Stenglein, M. D., Fahrenkrug, S. C., Andresdottir, V., Harris, R. S. (2006). Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res 34: 5683-5694 [Abstract] [Full Text]  
  • Dang, Y., Wang, X., Esselman, W. J., Zheng, Y.-H. (2006). Identification of APOBEC3DE as Another Antiretroviral Factor from the Human APOBEC Family. J. Virol. 80: 10522-10533 [Abstract] [Full Text]  
  • Kozak, S. L., Marin, M., Rose, K. M., Bystrom, C., Kabat, D. (2006). The Anti-HIV-1 Editing Enzyme APOBEC3G Binds HIV-1 RNA and Messenger RNAs That Shuttle between Polysomes and Stress Granules. J. Biol. Chem. 281: 29105-29119 [Abstract] [Full Text]  
  • Iwatani, Y., Takeuchi, H., Strebel, K., Levin, J. G. (2006). Biochemical Activities of Highly Purified, Catalytically Active Human APOBEC3G: Correlation with Antiviral Effect.. J. Virol. 80: 5992-6002 [Abstract] [Full Text]  
  • Roy, B. B., Hu, J., Guo, X., Russell, R. S., Guo, F., Kleiman, L., Liang, C. (2006). Association of RNA Helicase A with Human Immunodeficiency Virus Type 1 Particles. J. Biol. Chem. 281: 12625-12635 [Abstract] [Full Text]  
  • Chiu, Y.-L., Greene, W. C. (2006). APOBEC3 Cytidine Deaminases: Distinct Antiviral Actions along the Retroviral Life Cycle. J. Biol. Chem. 281: 8309-8312 [Abstract] [Full Text]  
  • Lingappa, J. R., Dooher, J. E., Newman, M. A., Kiser, P. K., Klein, K. C. (2006). Basic Residues in the Nucleocapsid Domain of Gag Are Required for Interaction of HIV-1 Gag with ABCE1 (HP68), a Cellular Protein Important for HIV-1 Capsid Assembly. J. Biol. Chem. 281: 3773-3784 [Abstract] [Full Text]  
  • Cullen, B. R. (2006). Role and Mechanism of Action of the APOBEC3 Family of Antiretroviral Resistance Factors. J. Virol. 80: 1067-1076 [Full Text]  
  • Bogerd, H. P., Wiegand, H. L., Doehle, B. P., Lueders, K. K., Cullen, B. R. (2006). APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res 34: 89-95 [Abstract] [Full Text]  
  • Russell, R. A., Wiegand, H. L., Moore, M. D., Schafer, A., McClure, M. O., Cullen, B. R. (2005). Foamy Virus Bet Proteins Function as Novel Inhibitors of the APOBEC3 Family of Innate Antiretroviral Defense Factors. J. Virol. 79: 8724-8731 [Abstract] [Full Text]  
  • Schumacher, A. J., Nissley, D. V., Harris, R. S. (2005). APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc. Natl. Acad. Sci. USA 102: 9854-9859 [Abstract] [Full Text]  
  • Doehle, B. P., Schafer, A., Wiegand, H. L., Bogerd, H. P., Cullen, B. R. (2005). Differential Sensitivity of Murine Leukemia Virus to APOBEC3-Mediated Inhibition Is Governed by Virion Exclusion. J. Virol. 79: 8201-8207 [Abstract] [Full Text]  
  • Hache, G., Liddament, M. T., Harris, R. S. (2005). The Retroviral Hypermutation Specificity of APOBEC3F and APOBEC3G Is Governed by the C-terminal DNA Cytosine Deaminase Domain. J. Biol. Chem. 280: 10920-10924 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zennou, V.
Right arrow Articles by Bieniasz, P. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zennou, V.
Right arrow Articles by Bieniasz, P. D.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»